Key result
Platelet-activating factor (PAF) is a potent phospholipid mediator with vital cell signalling functions and a pro-inflammatory role in chronic diseases including cardiovascular disease and cancer.
Why the study?
Marking forty years since the structural elucidation of platelet-activating factor, this review provides a historical account of its discovery and an overview of current and future research perspectives in physiology and pathophysiology.
This review summarizes the 40-year history of platelet-activating factor research, highlighting its role as a pro-inflammatory molecule in chronic diseases.
No immediate change to CVD management; leaves open PAF-targeted therapies for prospective trials.
In the late 1960s, Barbaro and Zvaifler described a substance that caused antigen induced histamine release from rabbit platelets producing antibodies in passive cutaneous anaphylaxis. Henson described a 'soluble factor' released from leukocytes that induced vasoactive amine release in platelets. Later observations by Siraganuan and Osler observed the existence of a diluted substance that had the capacity to cause platelet activation. In 1972, the term platelet-activating factor (PAF) was coined by Benveniste, Henson, and Cochrane. The structure of PAF was later elucidated by Demopoulos, Pinckard, and Hanahan in 1979. These studies introduced the research world to PAF, which is now recognised as a potent phospholipid mediator. Since its introduction to the literature, research on PAF has grown due to interest in its vital cell signalling functions and more sinisterly its role as a pro-inflammatory molecule in several chronic diseases including cardiovascular disease and cancer. As it is forty years since the structural elucidation of PAF, the aim of this review is to provide a historical account of the discovery of PAF and to provide a general overview of current and future perspectives on PAF research in physiology and pathophysiology.
No takes yet. Share an insight, caveat, or question.
Lordan et al. (2019) conducted a review in Cardiovascular disease and cancer. Platelet-activating factor (PAF) was evaluated. Platelet-activating factor (PAF) is a potent phospholipid mediator with vital cell signalling functions and a pro-inflammatory role in chronic diseases including cardiovascular disease and cancer.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: